
Medtronic plc

MDT (Medtronic plc) trades at 3.4x EV/Revenue — attractively valued for a healthcare & pharma company with strong gross margins (65%) and moderate growth (+7% YoY). The business is profitable at 28% EBIT margins. Forward PE of 14x.
When CEOs buy their own stock in the open market, the stock outperforms by 8.9% on average over the following year.
Medtronic is a global medical technology leader that develops and manufactures medical devices, therapies, and software solutions for hospitals and healthcare providers worldwide. The company operates across four main segments: Cardiovascular (pacemakers, stents), Medical Surgical (surgical tools, patient monitoring), Neuroscience (spinal devices, brain stimulators), and Diabetes (insulin pumps, continuous glucose monitors). They generate revenue through device sales, recurring revenue from supplies and services, and software licensing.
Medtronic is positioned to benefit from global aging demographics driving increased demand for cardiovascular and diabetes care solutions. The company is targeting mid-single-digit organic revenue growth through portfolio optimization, geographic expansion in emerging markets, and breakthrough technologies in robotics and AI-assisted procedures. Key growth drivers include their Hugo robotic surgery platform and advanced diabetes management ecosystem.
The company maintains strong gross margins typically in the 65-70% range due to the specialized nature of medical devices and regulatory barriers to entry. Operating margins have faced pressure from increased R&D investment and competitive dynamics but remain robust in the high-teens to low-20% range. Medtronic generates consistent free cash flow, supporting its dividend aristocrat status with over 40 years of consecutive dividend increases.
Medtronic competes with large medtech players like Abbott, Boston Scientific, and Johnson & Johnson across various segments, while also facing specialized competitors in each business line. The company's competitive advantages include its scale in R&D, global distribution network, comprehensive product portfolios, and strong relationships with healthcare providers built over decades of market presence.
*Note: Specific recent quarter performance data was not available in the provided information. Recent momentum analysis would require current earnings data, stock performance, and latest financial results.*
*Note: Current analyst sentiment, consensus estimates, and Wall Street debates would require access to recent research reports and earnings expectations data not provided in the source material.*
Medtronic is a defensive healthcare play offering steady growth exposure to aging demographics and medical innovation, backed by strong market positions and consistent cash generation, though growth rates may be modest compared to higher-growth medtech peers.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | $36.2B | $38.6B | $40.6B | $43.3B |
| Growth | — | +7% | +5% | +6% |
| EBITDA | — | $11.1B | $11.7B | $12.5B |
| Growth | — | +5% | +6% | |
| FCF | $5.2B | — | — | — |
| Margin | 14% | — |
Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript
Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
MiniMed Group: Medtronic's Diabetes Business Does Not Convince
Medtronic's diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
| — |
| — |
| EPS (PF) | $5.65 | $6.09 | $6.54 | $7.14 |
| Growth | — | +8% | +7% | +9% |